Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK health agency

This article was originally published in The Tan Sheet

Executive Summary

Medicines & Healthcare Products Regulatory Agency will become official April 1 with new Web site at http://www.mhra.gov.uk. MHRA will consist of Medicines Control Agency and Medical Devices Agency; merger was initiated in June 2002 to address convergence of drug, medical device fields (1"The Tan Sheet" June 17, 2002, In Brief)...

You may also be interested in...



UK health agency merger

Medicines Control Agency, Medical Devices Agency will merge into single, as-yet-unnamed entity next April due to increasing convergence in drug, medical device fields, Department of Health announces June 13. Systems and processes by which drugs are licensed, medical devices are controlled will not be affected, but merger will include creation of chairman post to serve as agency's authoritative figurehead and oversee strategic management. Agency also will have a chief executive; current MCA Chief Exec Keith Jones, MD, is leaving his post in October...

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

Topics

UsernamePublicRestriction

Register

ID1125791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel